road ahead for immunotherapy in hodgkin lymphoma: bispecifics & car-t
Published 5 years ago • 260 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t
-
1:48
novel immunotherapy approaches in lymphoma: car-t cells, bispecifics & sequencing
-
2:00
the incorporation of immunotherapy into frontline all treatment
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
1:57
the current hodgkin lymphoma immunotherapy landscape
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
1:18
advances in immunotherapy for lymphoma
-
1:55
optimal sequencing of car-t and bispecifics in nhl
-
1:51
investigating resistance mechanisms to bispecific antibodies and car-t in patients with lymphoma
-
1:18
the role of cellular immunotherapies in the future treatment of hl
-
1:15
the role of bispecific antibodies in the treatment of r/r large b-cell lymphoma
-
2:29
the safety and feasibility of car-t & bispecifics in patients with myeloma after prior allosct
-
3:32
improving car-t therapy for all & lymphoma: allogeneic products & reducing crs/icans
-
1:17
the importance of risk-adapted therapies in hodgkin lymphoma
-
2:29
emerging lymphoma therapies: bispecific antibodies and car t-cells
-
1:50
should bispecifics or car-t be given first in r/r fl?
-
2:55
post-transplant pd1 blockade plus autologous lymphocytes in r/r hl